pipeline-prospector-insert-v1
X

Find Clinical Drug Pipelines for Pulmonary/Respiratory Diseases

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Study Phase filter
    Country filter
      News Type filter
        Company filter
          Product Type filter
            refresh

            Product Type

            Development Status

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mometasone Furoate

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Perceptive Advisors

            Deal Size: $30.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing January 29, 2020

            Details:

            Lyra plans to use the proceeds for the advancement of the company’s lead product candidates, LYR-210 and LYR‑220, and for general corporate purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sodium Fusidate

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 28, 2020

            Details:

            ARV-1801 is one of the very few oral antibiotics that has increased potency in low pH environments and also has anti-inflammatory activity.

            Bill & Melinda Gates Medical Research Institute

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): M72/AS01E

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: GlaxoSmithKline

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 27, 2020

            Details:

            Gates MRI has licensed the vaccine from GSK. Having done so, Gates MRI will lead development of the vaccine and sponsor future clinical trials. GSK will continue to supply the adjuvant, AS01, only.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sotatercept

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 27, 2020

            Details:

            The PULSAR trial achieved its primary endpoint: a statistically significant reduction in pulmonary vascular resistance

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tipelukast

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 27, 2020

            Details:

            The allowed claims cover the use of MN-001 for treating a patient diagnosed with idiopathic pulmonary fibrosis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ifenprodil Tartrate

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 17, 2020

            Details:

            Algernon Pharma has appointed Novotech as the contract research organization for the its upcoming Phase 2 idiopathic pulmonary fibrosis and chronic cough study for the drug candidate NP-120.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pretomanid

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: TB Alliance

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 16, 2020

            Details:

            The partnership with Hongqi is part of TB Alliance’s global commercialization strategy for pretomanid as part of the BPaL regimen.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MultiStem cell therapy

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 14, 2020

            Details:

            One-year results support positive 28-day findings and suggest further benefits for ARDS patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Levosimendan

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 13, 2020

            Details:

            Tenax Therapeutics reports that till now 24 patients have been randomized, pulmonary capillary wedge pressure was reduced and no serious drug-related adverse events have been reported to date.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rpl-554

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 13, 2020

            Details:

            Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant dose-dependent improvements in lung function.

            PharmaCompass